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Abstract 
Since its first emergence from China in late 2019, the SARS-CoV-2 virus has spread globally 
despite unprecedented containment efforts, resulting in a catastrophic worldwide pandemic. 
Successful identification and isolation of infected individuals can drastically curtail virus spread 
and limit outbreaks. However, during the early stages of global transmission, point-of-care 
diagnostics were largely unavailable and continue to remain difficult to procure, greatly inhibiting 
public health efforts to mitigate spread. Furthermore, the most prevalent testing kits rely on reagent- 
and time-intensive protocols to detect viral RNA, preventing rapid and cost-effective diagnosis. 
Therefore the development of an extensive toolkit for point-of-care diagnostics that is expeditiously 
adaptable to new emerging pathogens is of critical public health importance. Recently, a number of 
novel CRISPR-based diagnostics have been developed to detect COVID-19. Herein, we outline the 
development of a CRISPR-based nucleic acid molecular diagnostic utilizing a Cas13d ribonuclease 
derived from Ruminococcus flavefaciens (CasRx) to detect SARS-CoV-2, an approach we term 
SENSR (Sensitive Enzymatic Nucleic-acid Sequence Reporter). We demonstrate SENSR robustly 
detects SARS-CoV-2 sequences in both synthetic and patient-derived samples by lateral flow and 
fluorescence, thus expanding the available point-of-care diagnostics to combat current and future 
pandemics.  
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Introduction 
Following emergence from China in late 2019 1–3, severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) 1,4 has spread to almost every country despite unprecedented control efforts 5. 
Compared to H1N1, Ebola, MERS, and SARS-CoV-1 outbreaks of recent decades, this novel 
coronavirus represents the first pandemic characterized by widespread global transmission coupled 
with significant mortality. Pre-symptomatic and asymptomatic carriers have been identified as 
major contributors to the prolific spread of SARS-CoV-2 4,6,7 however, in many cases these patients 
go unidentified and unisolated, exacerbating the spread of the disease. Thus, robust identification 
and isolation of all infected individuals are essential for controlling disease transmission. The 
SARS-CoV-2 pandemic thus presents an unparalleled global public health emergency, which 
spurred the urgent development of molecular diagnostics and therapeutics for timely patient 
identification, isolation and treatment. The economic, health, and societal damage wrought by 
SARS-CoV-2, highlights the importance of expanding and improving on current diagnostic 
technologies to identify and prevent future pandemics.  
  
Early diagnostics detected SARS-CoV-2 infection through the amplification of viral RNA (vRNA) 
by real-time reverse transcription polymerase chain reaction (RT-PCR) 8–10. These tests were time 
consuming 11, limited by reagents 12, required advanced equipment, and yielded significant false-
negatives 13–16 possibly exacerbated by genetic variation within the targeted viral genomic 
sequences 17.  Next generation sequencing-based diagnostics reduced false-negative rates, but still 
require specialized equipment and are slow (~12 hours) 18. Therefore, developing alternative 
technologies with the potential to yield cost- and time-effective point-of-care diagnostics demands 
investment. 
 
CRISPR-Cas nucleases can be easily programmed to target nucleic acids in a sequence-specific 
manner 19–21, making them prime candidates for the detection and diagnosis of viral genetic 
material, and forming the CRISPR-based diagnostics (CRISPRDx) pipeline 22–25. These systems 
rely on Type II Cas enzymes to physically bind target sequences 26, or collateral cleavage by Type 
V or Type VI enzymes to detect DNA 24,25,27 or RNA species, respectively 22,23,28. Since pandemic 
onset, an array of innovative diagnostics and prophylactics relying on these technologies have been 
adapted to detect or target SARS-CoV-2 with unprecedented speed 26,29–40, most notably 
represented by the DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter) 24,25 and 
SHERLOCK (Specific High-Sensitivity Enzymatic Reporter unLOCKing) 22,23 systems 
(Summarized in Fig. S1, Table S1). 
 
The SHERLOCK system combines isothermal amplification of target sequences, followed by target 
recognition via Leptotrichia wadei Cas13a (LwaCas13a) and collateral cleavage of a bystander 
ssRNA probe to report the presence of a target 22. This system has undergone significant 
optimization since its first development in 2017. This includes improvement of i) sensitivity, by the 
inclusion of an accessory protein to amplify signal or substitution of RPA with LAMP 23,41,42, ii) 
specificity, by primer and guide optimization 22,23, iii) throughput, by multiplexing detection using 
additional enzymes (including a cocktail of LwaCas13a, PsmCas13b (Prevotella sp. MA2016), 
CcaCas13b (Capnocytophaga canimorsus Cc5), and AsCas12a (Acidaminococcus sp. BV3L6)) 23, 
and iv) validation as a point-of-care diagnostic by using lateral flow and ultrafast RNA extraction 
methods 23,31,33,43. Ideally, to maximize all the capabilities of SHERLOCK and expand the 
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CRISPRDx toolkit, it is important to evaluate alternative Cas enzymes that can complement or 
supplement the system. 
 
Similar to Cas ribonucleases used in other CRISPRDx systems, Cas13d enzymes such as 
RfxCas13d (CasRx), exclusively target RNA species that trigger subsequent collateral cleavage of 
bystander RNA 44–46. Collateral cleavage is initiated following on-target ssRNA cleavage by the 
HEPN domain-based endoRNase heterodimer, which activates trans-cleavage of nonspecific 
bystander RNAs 20,44,46,47. Furthermore, Cas13d enzymes are approximately 20% smaller than 
Cas13a-Cas13c effectors, and do not require a Protospacer Flanking Sequence (PFS) 20,44,46,48, 
presenting an advantage for protein production and flexible targeting. While the genetic modulatory 
effects of CasRx have been thoroughly characterized in Drosophila, zebrafish, and human cells 
44,45,49, and its putative prophylactic properties against SARS-CoV-2 have been demonstrated 40, its 
potential as a diagnostic system has not yet been explored.  
 
In an effort to expand the CRISPRDx toolkit, herein, we report the first use of CasRx 44 as a 
molecular diagnostic, developing a unique system we term SENSR (Sensitive Enzymatic Nucleic-
acid Sequence Reporter) and demonstrating robust detection of SARS-CoV-2 viral sequences (Fig. 
1A). Following on-target cleavage, CasRx exhibits collateral cleavage of off-target nucleic acids 
44,45, a feature shared by Cas nucleases used in other CRISPRDx systems 22–25. We exploit the 
collateral cleavage activity of CasRx to detect SARS-CoV-2 in both synthetic templates as well as 
in patient-derived samples via fluorescence-based readout, and paper-based lateral flow assay. To 
maximize specificity, we performed an extensive bioinformatic analysis to identify novel conserved 
and specific viral targets to minimize false-negative and false-positive rates, respectively. We 
demonstrate that SENSR facilitates attomolar sensitivity in just under two hours total reaction time. 
The detection limit of SENSR is comparable to, though slightly less than, previously established 
CRISPRDx systems 31,35,38 and shows promise for improvement.  
 
Results 
 
Development of the SENSR protocol 
 
Derived from protocols originally developed for (Fig. S1, Table S1) SHERLOCK 22,23,31,48, we 
designed a two-step protocol for the detection of nucleic acids using recombinant CasRx purified 
after expression in E. coli (Fig. S2). The protocol requires an initial 45-minute isothermal 
preamplification reaction combining reverse transcriptase and recombinase polymerase 
amplification (RT-RPA) 50 producing a short dsDNA amplicon encompassing the CasRx target site 
and containing a T7 promoter sequence. This is followed by an in vitro transcription (IVT)-coupled 
cleavage reaction which converts the dsDNA amplicons into ssRNA, recognizable by CasRx for 
cleavage, resulting in collateral cleavage of a bystander ssRNA probe. Collateral cleavage of the 
probe is analyzed by either fluorescence or lateral flow readouts, thus indicating the initial presence 
or absence of SARS-CoV-2 genomic sequences (Fig. 1A, Fig S3).  
 
Target selection and reagent validation 
 
To ensure high analytical specificity, we identified conserved gRNA target sites using a 
bioinformatic pipeline to identify 30 nt target sequences conserved among the first 433 published 
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SARS-CoV-2 genomes available at Genbank on April 7th, 2020, and without homology to other 
coronaviruses (ViPR, Virus Pathogen Resource, n = 3,164). This yielded a panel of gRNA target 
sites (n=8846) less likely to result in false positives or negatives due to sequence constraints (Fig. 
S4, Table S2, S3). Because RT-qPCR assays recommended by the WHO and CDC target the 
envelope (E) and nucleocapsid (N) genes within the SARS-CoV-2 genome, we selected these genes 
as the targets of SENSR for system validation (Fig. 1B) 8,51. The bioinformatic analysis revealed 
multiple specific sequences within the N-gene (n = 150), to which we designed three gRNAs 
(gRNA-Z, -AA, -AC) (Table S2, Fig. S5A). However, the stringent bioinformatic search criteria 
did not identify targets specific to SARS-CoV-2 within the E-gene due to high sequence homology 
with the SARS-CoV-1 E-gene. We, therefore, relaxed the criteria to include target sites sharing 
homology with distantly related SARS-CoV-1 which is presently absent from the general 
population. From this, we selected three E-targeting guides (gRNA-R, -T, -V), with two displaying 
complete (gRNA-T (433/433), gRNA-V (433/433)) and one with nearly complete (gRNA-R 
(430/433)) conservation among the available SARS-CoV-2 genomes (Table S4, Fig. S5A). To 
validate these gRNAs, we generated synthetic SARS-CoV-2 targets encompassing the E- and N-
genes (Table S5), and tested for in vitro cleavage with purified CasRx protein (Fig. S2). Initial 
characterization of on-target cleavage properties revealed significant degradation of target 
transcripts for all guides tested (Fig. S5B, C) motivating further assessment of all candidates. To 
determine the most effective gRNAs for use in SENSR, we monitored fluorescence accumulation 
over time in an IVT-coupled cleavage reaction for each gRNA. All gRNAs induced robust 
fluorescence within minutes, with the exception of gRNA-AA and -AC which produced no signal 
(Fig. 1C, D). gRNA-T (E-targeting) and gRNA-Z (N-targeting) were selected for downstream 
analysis due to their robust cleavage activity as well as sequence conservation among all publicly 
available SARS-CoV-2 patient sample isolates (Fig. 1B-D, Table S2, S3).  
 
Fluorescence-based detection of SARS-CoV-2 
 
We and others have recently demonstrated that on-target cleavage activates a secondary collateral 
cleavage property of CasRx 44,45. We initially evaluated the in vitro collateral cleavage activity of 
CasRx with gRNA-T and gRNA-Z through gel electrophoresis. By incubating CasRx, gRNA-T or 
gRNA-Z, and varying the addition of synthetic templates, we found CasRx collateral cleavage was 
only activated when the synthetic template added complemented the gRNA target sequence (Fig. 
1E, F). We sought to exploit this tandem, collateral cleavage activity to cleave a bystander 
fluorescent probe in trans, facilitating detection of SARS-CoV-2 by fluorimetry (Fig. 1A, Fig. S3). 
The quenched fluorescent reporter within RNaseAlert v2 has been used to report collateral cleavage 
of Leptotrichia wadeii (LwaCas13a), Capnocytophaga canimorsus Cc5 (CcaCas13b), and 
PsmCas13b (Prevotella sp. P5-125) in the SHERLOCK systems 22,23,48, but our preliminary analysis 
of RNaseAlert v2 failed to yield fluorescence with CasRx in the presence of a synthetic target 
(Student’s t-test gRNA-T: p=0.4294, gRNA-Z: p=0.1510) (Fig. S6A). Prior work suggested CasRx 
preferentially cleaves targets containing poly-U stretches 44, with complementary work 
demonstrating collateral cleavage of targets rich in both poly-A and poly-U stretches 46. To develop 
a probe cleavable by CasRx, we therefore generated two custom 6 nucleotide ssRNA probes, poly-
A and poly-U, each conjugated to a 5’ fluorescent molecule (6-FAM) and a 3’ fluorescence 
quencher (FQ), whose separation following cleavage results in detectable fluorescence 
accumulation (Fig. 1A). Following incubation of CasRx, with either gRNA-T or -Z, in the presence 
or absence of their respective synthetic targets (E- or N-gene), the poly-U probe yielded significant 
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fluorescence for 10000 copies/𝜇L compared to the no-template control (NTC) (Student’s t-test 
gRNA-T, gRNA-Z: p<0.0001), while the poly-A probe produced no detectable fluorescence signal 
(Student’s t-test gRNA-T: p=0.5953, gRNA-Z: p=0.7935), suggesting a preference for poly-U 
stretches by CasRx, and motivating its use in the remainder of experiments (Fig. S6A, Table S5). 
 
Following probe selection, we moved to evaluate the collateral cleavage activity in the context of 
fluorescence. We set to determine if the gRNA incubated with the respective target sequence 
dictates the increase in fluorescence signal over time. To do so, we incubated CasRx, gRNA-T or 
gRNA-Z, the modified poly-U probe, and varied the addition of synthetic templates, while 
fluorescence data were acquired on a plate reader. We observed fluorescence signal only 
accumulated, and thus collateral cleavage activated, when the synthetic template added to the 
reaction complemented the gRNA target sequence (Fig. 2A, B). After optimizing preamplification 
reaction input volume using 100 copies/𝜇L of synthetic RNA, and determining 50% 
preamplification reaction volume input to be optimal (Fig. S6B), we then determined the LOD by 
fluorescence for gRNA-T and gRNA-Z titrated at log scale from 10,000 to 0 copies/𝜇L. We 
determined the LOD to be 100 copies/𝜇L (Fig. 2C, D), indicating SENSR exhibits attomolar 
sensitivity comparable to other CRISPRDx systems 22,24. These results demonstrate CasRx can 
robustly detect and report the presence of synthetic SARS-CoV-2 RNA via fluorescence readout.  
 
Lateral flow assay development 
 
Collateral cleavage by CasRx can additionally be exploited to detect synthetic SARS-CoV-2 RNA 
by lateral flow assay, facilitating detection by simple paper test strip and eliminating the need for 
expensive laboratory equipment (Fig. 1A, Fig. S3). Similar to assays developed by others 23,48, we 
developed a 6 nucleotide ssRNA probe conjugated with 5’ 6-FAM and 3’ biotin (Bio) compatible 
with Millenia HybriDetect lateral flow strips (Table S5). In brief, collateral cleavage results in 
separation of 6-FAM from biotin, detectable following capillary action down a paper dipstick 
imprinted with streptavidin or anti-FAM secondary antibodies at distant ends (Fig. 1A). The 
absence or presence of the upper band therefore indicates a negative or positive result, respectively 
(Summarized in Fig. 1A, Fig. S3). Using this protocol, we demonstrated that SENSR can be 
adaptable to readout by lateral flow, and determined the LOD of synthetic SARS-CoV-2 RNA to 
be as low as ~100 copies/𝜇L, however with variability between guides (Fig. 2E, F). These results 
confirm that SENSR, like other CRISPRDx systems, can be adapted for read-out by lateral flow, 
indicating the potential for future application within point-of-care rapid diagnostic tests. 
 
Specificity of SENSR against known possible off-targets 
 
Diagnostic assays require stringent specificity parameters to limit false- negatives/positives. 
Because many Cas effectors tolerate some degree of mismatch 52–54, unintended false-positives can 
occur as a result of cleaving closely related off-target sequences. In a health-care setting, SENSR 
is unlikely to be exposed to randomly generated high-identity sequences, and will more likely 
encounter closely related natural homologs. Therefore, we identified the four highest-identity 
natural homologous sequences to the gRNA-T and gRNA-Z target sites via BLAST.  In each case, 
SARS-CoV-1 variants, Bat coronaviruses, and Pangolin coronaviruses were identified as the most 
closely related potential off-targets (OT), containing 2 or 3 mismatches, with gRNA-Z also 
targeting an additional unknown marine virus and a porcine genome sequence with 7 mismatches 
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(Fig. S7A, B, Table S6).  We synthesized these sequences as DNA templates containing a T7 
promoter and assayed for off-target cleavage tolerance of gRNA-T and gRNA-Z in an IVT-coupled 
cleavage reaction analyzed via fluorescence detection. We found that gRNA-T was sufficiently 
specific to exclusively recognize the synthetic E-gene fragment (ANOVA, p<0.001), precluding 
recognition of any off-targets, which showed no significant differences in fluorescent signal with 
the NTC (ANOVA, Dunnett’s test OT1: p=0.9998, OT2: p=0.5242, OT3: p=0.6633, OT4: 
p=0.8475) (Fig. S7C). gRNA-Z demonstrated detection of the N-gene synthetic template and the 
most similar pangolin coronavirus off-target templates compared to the NTC (N, OT1, OT2: 
p<0.0001), thus presenting some degree of mismatch tolerance for gRNA-Z. Fluorescence signal 
for OT3 and OT4 did not differ from the NTC (ANOVA, Dunnett’s test OT3: p=0.8877, OT4: 
p>0.9999) (Fig. S7D). 
 
CasRx-based detection of SARS-CoV-2 from patient isolates 
 
We next sought to determine the capability of SENSR to detect SARS-CoV-2 from infected patient 
samples and directly compared these results to RT-qPCR-validated diagnostics. RT-qPCR analysis 
of patient samples was performed by targeting the N-, S-, and Orf1ab-genes (Table S7), and 
accordingly, we selected gRNA-Z to directly compare SENSR fluorescence detection to N-gene 
RT-qPCR Ct values. We performed fluorescence detection analysis on 42 RT-qPCR validated 
positive (n = 21) and negative (n = 21) patient samples. By fluorescence, SENSR yielded no false-
positives among negative patient samples demonstrating 100% specificity (0/21), and obtained a 
conservative 57% concordance with confirmed positive samples (12/21) when the threshold for 
detection is set at S/N > 2 (Fig. 3A, B, Table S7). For RT-qPCR analysis of viral infections, a lower 
Ct value indicates a higher viral load within an isolated sample. SENSR demonstrated robust 
detection of infected patient samples with Ct values ≤ 20, detecting SARS-CoV-2 vRNA in (8/9) 
such samples (Sample ID: 1-9) (Fig. 3A, Table S7). SENSR could detect SARS-CoV-2 vRNA up 
to a maximum Ct value ≤ 28 with a moderate 25% (4/16) false-negative rate (Fig. 3A, B, Table 
S7). Next, we confirmed detection of SARS-CoV-2 can be achieved by lateral flow analysis. We 
performed lateral flow analysis on the 12 positive samples resulting in S/N > 2, and correlating to 
a Ct ≤ 28, to determine if SENSR can operate as a point-of-care diagnostic. Using lateral flow, we 
observed 92% (11/12) concordance with SENSR fluorescence analysis (Fig. 3C). These findings 
confirm SENSR can be successfully adapted for the rapid detection of SARS-CoV-2 from patient 
samples, however, further optimization will be required to improve sensitivity and consistency. 
 
Discussion 
 
With an increasingly interconnected world and expanding global population, future pandemics are 
inevitable. The COVID-19 pandemic spread prolifically in the early months of 2020, with 
containment elusive in part due to the scarcity of point-of-care diagnostics. The seemingly infinite 
adaptability of CRISPR has, or promises to, accelerate the development of everything from life-
saving gene therapies 55–57  and pig-to-human organ donations 58; to disease-eradicating gene drives 
59–61 and possibly the re-animation of the Woolly Mammoth 62,63 - with CRISPR-based diagnostics 
(CRISPRDx) being no exception. Though still nascent, CRISPRDx, like other CRISPR 
technologies, has proven fast to develop, highly flexible, capable of multiplexing, making it the 
ideal toolkit from which to develop expeditious future point-of-care diagnostics. The CRISPRDx 
technologies developed prior to the COVID-19 pandemic, such as SHERLOCK and DETECTR, 
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may have helped halt disease transmission had they been deployed earlier and implemented more 
widely. Therefore, it is important to prepare now, well in advance of the next pandemic, by 
perfecting and expanding the CRISPRDx toolkit to the bounds of its capabilities. 
 
Complementing the rapidly expanding CRISPRDx toolkit (Fig. S1, Table S1), here we outline the 
use of RfxCas13d (CasRx) to diagnose SARS-CoV-2 using both synthetic targets and patient 
derived samples. SENSR amplifies nucleic acid sequences through an isothermal alternative to PCR 
then detects the target sequences by exploiting the native collateral cleavage activity of CasRx (Fig. 
1A), providing proof-of-principle that Cas13d can be adapted as a point-of-care diagnostic. We 
lend further evidence that CasRx cleavage results in activation of an off-target collateral cleavage 
property (Fig. 1 E, F) 44,64, with a preference for poly-U stretches (Fig. S6A).  This feature can be 
harnessed to detect viral sequences in a single reaction or possibly even in a multiplexed reaction 
combined with other Cas enzymes lacking a poly-U preference 23,48. We identify highly conserved 
and specific targets to SARS-CoV-2 to prevent false-negatives (Fig. S4, Table S2, S3), and 
demonstrate detection with attomolar sensitivity by both fluorescence and lateral flow readouts 
comparable to other previously developed systems (Fig. 2C-F) 31,38,39,65. We further demonstrate 
that SENSR has the potential to be so specific to SARS-CoV-2, and further prove it can be adapted 
to detect vRNA in infected patient isolates (Fig. 3A-C). 
 
SENSR provides a robust proof-of-principle of viral detection by CasRx, and as such, it should be 
considered a candidate diagnostic system; however, it requires optimization in advance of 
deployment. Optimizing SENSR diagnostics can be pursued through a number of avenues. While 
some groups have improved specificity by selectively generating synthetic mismatches in guide 
sequences 22, the gRNAs tested herein have moderate target specificity (Fig. S7). RT-RPA also 
exhibits nonspecific amplification 66–68, and therefore, alternative isothermal amplification 
technologies, such as RT-LAMP 41,69, could be implemented to improve specificity. Although RT-
LAMP is likely to improve specificity as well as sensitivity, the requirement of two separate 
reactions remains problematic, increasing the likelihood of contamination due to sample transfers 
70. RT-LAMP and CasRx operate optimally at divergent temperatures (60-65℃ and 37℃, 
respectively), which may be incompatible within a one-step molecular diagnostic, though advances 
have been made in this sphere 33,71,72. Thus alterations to existing isothermal amplification 
technologies or discovery of novel thermostable Cas nucleases with collateral cleavage activity 
could facilitate a more highly-sensitive Cas-based molecular diagnostic that operates in one reaction 
at a single temperature.  
 
Beyond amplification, improvement to gRNA design criteria could drastically improve gRNA 
selection for diagnosis and consequently the response time to future disease outbreaks. Currently, 
there remains no robust study attempting to characterize the in vitro collateral cleavage activity for 
varying Cas13 gRNA sequences, thus limiting efficient gRNA design and target selection for 
Cas13-based diagnostics. In this study, we observed significant variation in gRNA collateral 
cleavage activity, including two gRNAs (gRNA-AA and gRNA-AC) incapable of producing 
fluorescence signal (Fig. 2A) and kinetic variation exemplified by temporal differences in 
fluorescence signal accumulation for gRNA-T and gRNA-Z (Fig. 1E, F). We also observed mild 
off-target activity for gRNA-Z (Fig. S7D) and found variation in reporter saturation for lateral flow 
between gRNAs (Fig. 2E, F), which has been found in other systems 31,38. Understanding gRNA-
specific differences of Cas13 collateral cleavage will allow the development of functional gRNA 
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target sequence libraries for use in future pandemics. Furthermore, robust exploration for CasRx 
gRNA truncations and permutations should be undertaken to generate gRNAs intolerant of target 
site polymorphisms, or to even distinguish between strains 22, thus improving the specificity of 
SENSR. Optimizing workflow, deployment, and distribution, while taking steps to reduce the risk 
of contamination, is imperative to develop CasRx-based diagnostics to their full potential. Although 
optimization is required, we demonstrate that detection with CasRx is a promising advancement for 
detecting viral infections, and could be improved to become a powerful molecular diagnostic with 
numerous applications.  
 
CasRx-based diagnostic systems may present a worthy advancement for CRISPRDx due to the 
fundamental characteristics of the Cas13d family. Like LwaCas13a, Cas13d is more flexible than 
most other Cas enzymes because it lacks a protospacer flanking sequence (PFS) requirement 28,44,46, 
permitting targeting of any sequence without constraint. In addition, some native Cas13d systems 
include a WYL1-domain-containing accessory protein, which has been demonstrated to increase 
the on-target and collateral cleavage efficiency of the Cas13d effectors 46,73, suggesting potential 
for future implementation. Furthermore, because they target RNA, next-generation Cas13-based 
systems may be capable of direct recognition of RNA, possibly at the single molecule level, without 
need for a prior reverse transcription (RT) and/or amplification step. This property could enable 
direct detection of many emerging viral threats including, but not limited to;  bunyaviruses 74, 
zoonotic viruses such as Ebola, hanta, and Lassa 75; arboviruses such as dengue, chikungunya, and 
Zika 23,76,77, and other coronaviruses such as MERS, SARS-CoV-1, as well as those yet 
undiscovered 78,79. CasRx-based diagnostics systems could detect endemic pathogens capable of 
zoonotic transmission through livestock and wild animals such as influenza or other coronaviruses 
78,80,81 which may have been able to prevent past pandemics 82, and avert mass herd culling resulting 
in billions of dollars of losses 83,84. Beyond detection in patients and livestock, SENSR could be 
adapted to detect pathogens in insect disease vectors as well as infected individuals 85, facilitating 
rapid one-pot field detection of mosquito-borne pathogens in areas lacking laboratory infrastructure 
86. However, SENSR is not limited to detection of RNA species, and could also be used to detect 
pathogen DNA (Fig. S8). By including an RNA polymerization step, this same technology could 
be harnessed to track evidence of insecticide resistance alleles 87, released transgenic cargoes 59,60, 
or the presence of Borrelia burgdorferi in a tick plucked from a hiker’s leg.  
 
Pushing the boundaries of viral sequence recognition with CRISPR-Cas nucleases is not only of 
interest for genetic engineering and diagnostics, but also for therapeutics as well. The adaptability 
of CasRx RNA-targeting has recently been demonstrated to be a potentially powerful anti-COVID 
therapeutic 40  as well as for other viruses 88.  Together with acute diagnostics, these technologies 
could promise a new mode of response to future viral outbreaks via a ‘plug-n-chug’ model, in which 
complementary diagnostics and therapeutics could be systematically rolled out almost immediately 
after completion of a viral genome sequence. Similar to LwaCas13a, CasRx could also be adapted 
to massively multiplexed arrays to facilitate identification of viral pathogens on a large scale 37.  
Establishing these tools and frameworks now, could expedite response times and help prevent 
future outbreaks, avoiding the economic and health consequences which have resulted from poor 
preparedness to the current pandemic. 
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Materials and Methods 
 
CasRx subcloning, protein expression and purification  
To produce an expression plasmid for CasRx protein production, we cloned the human codon 
optimized CasRx coding sequence into the expression vector, pET-His6-MBP-TEV-yORF (Series 
1-M) (purchased from QB3 MacroLab, Berkeley) using the Gibson assembly method (Gibson et 
al., 2009). In brief, the CasRx coding sequence was PCR amplified from plasmid OA-1050E 
(Addgene plasmid # 13241664) using primers 1136I.C1 and 1136I.C2 (Table S5). The fragment 
was purified and subcloned into the restriction enzyme cutting site EcoRI, downstream of the His-
MBP recombinant protein in pET-His6-MBP-TEV-yORF, generating the final pET-6xHis-MBP-
TEV-CasRx (OA-1136J; Addgene plasmid # 153023) plasmid.   
 
Protein expression, culture, cell lysis,  affinity and further downstream protein purification were 
performed as previously described (Fig. S2) 44. In brief, to facilitate protein expression in liquid 
culture, pET-His6-MBP-TEV-CasRx was transformed into Rosetta2 (DE3) pLysS cells (Novagen, 
71403). Starter cultures in LB were supplemented with kanamycin and chloramphenicol and 
incubated at 37° C overnight. 20 mL of starter culture were used to inoculate 1L of TB media 
supplemented with the same antibiotics. Cultures were allowed to grow until OD600 ~0.5, cooled 
on ice, induced with 0.2 mM IPTG, and then grown for 20 hours at 18° C. Cells were then pelleted, 
freeze-thawed, resuspended, lysed via sonication and clarified by centrifugation. Protein 
purification was performed by gravity Ni-NTA affinity chromatography (Thermo Scientific™ 
HisPur™ Ni-NTA Resin) followed by removal of the 6xHis-MBP tag by TEV protease 
concurrently with overnight dialysis. Further purification was achieved by cation exchange using a 
5-mL HiTrap SP HP using a gradient of 125 mM to 2M NaCl in 50 mM Tris-HCl, 7.5% v/v 
glycerol, 1 mM DTT. The protein was finally purified by gel filtration chromatography in 50 mM 
Tris-HCl, 600 mM NaCl, 10% glycerol, 2 mM dithiothreitol on a Superdex® 200 16/600 column. 
Fractions were pooled, concentrated to ~ 2 mg/mL and stored at -80 C in the same buffer. 
 
 
Production of target SARS-CoV-2 RNA and gRNAs 
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To detect viral genomic sequences, we designed two synthetic dsDNA gene fragments containing 
a T7 promoter sequence upstream of gene segments corresponding to the SARS-CoV-2 envelope 
(E) and nucleocapsid (N) protein coding regions (GeneBank Accession # MN908947). The 253bp 
SARS-CoV2 E-gene segment was ordered and synthesized as a custom gBlock® from Integrated 
DNA Technologies (IDT) and amplified using primers 1136Q-F and 1136Q-R (Table S5). A 500bp 
SARS-CoV2 N-gene segment was amplified from a plasmid 1136Y (Catalog # 10006625) 65 using 
primers 1136X-F and 1136X-R (Table S5). These two SARS-CoV-2 gene targets were amplified 
using PCR and then purified using the MinElute PCR Purification Kit (QIAGEN #28004). We also 
designed eight synthetic dsDNA templates containing nucleotide variations from the native SARS-
CoV-2 E- and N-gene (4 synthetic targets each gene) that were used for gRNA off-target analysis 
and ordered as a gBlock® from IDT. Primers 1136-OFF-F and 1136-OFF-R1~1136-OFF-R5 were 
used to amplify these sequences (Table S5). The synthetic targets were chosen based on sequence 
homology identified using NCBI BLAST searches against gRNA-T and gRNA-Z. 40nt regions 
flanking the mismatch target sequences were included in the 5’ and 3’ ends of the 30 nt stretch in 
order to allow amplification analysis via RT-RPA. 
 
We designed gRNAs targeting the synthetic vRNA gene segments using criteria previously outlined 
(Fig. S5) 64 and generated these following a previously described templateless PCR protocol 89. The 
primers used to amplify these gRNAs, as well as their final sequence are outlined in Table S5. We 
synthesized both the synthetic vRNA and gRNAs through in vitro transcription (IVT) using 
MEGAscriptTM T7 Transcription Kit (InvitrogenTM #AM1334), followed by DNaseI digestion and 
purification using the MEGAclearTM Transcription Clean-Up Kit (InvitrogenTM #AM1908).  
 
In vitro gRNA cleavage assays 
To test the in vitro cleavage efficiency of gRNAs, we performed preliminary in vitro cleavage 
assays to test on-target cleavage, off-target cleavage, and collateral-cleavage properties. On-target 
cleavage assays were prepared with RNA templates for E-gene (1000 ng) or N-gene (1500 ng), 
followed by addition of CasRx (112 ng) and 10 ng of each gRNA in a 2:1 molar ratio. Reactions 
were prepared in 20 mM HEPES pH 7.2 and 9mM MgCl2, incubated at 37℃ for one hour, 
denatured at 85℃ for 10 min in 2X RNA loading dye (New England Biolabs, #B0363) and loaded 
on 2% 1X TBE agarose gel stained with SYBRTM gold nucleic acid staining (Invitrogen #S11494). 
Off-target cleavage assays were assembled similarly with the non-targeting synthetic vRNA 
template. Collateral-cleavage assays were prepared with both synthetic vRNA templates 
simultaneously and same quantities of gRNA and CasRx described above.  
 
Bioinformatics of SARS-CoV-2 SENSR target sites. 
433 SARS-CoV-2 genomes were downloaded from NCBI Virus 
(https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&VirusLineage_ss=
SARS-CoV-2,%20taxid:2697049) and 3,164 non-SARS-CoV-2 Coronavirinae genomes were 
downloaded from Virus Pathogen Resource 
(https://www.viprbrc.org/brc/home.spg?decorator=corona_ncov) on April 7, 2020. To assess the 
specificity of our probes, all possible 30 nt sequences were extracted from the two genome sets 
using a Perl script (File S1) generating 52,712 and 8,338,305 unique fragments from SARS-CoV-
2 and non-SARS-CoV-2 genomes, respectively. The probes designed to target E and N genes based 
on Corman et al. 2020 (https://www.eurosurveillance.org/content/10.2807/1560-
7917.ES.2020.25.3.2000045 ) were cross-referenced against the extracted sequences to identify 
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numbers of targeted genomes in each set. Four of six probes perfectly matched sequences in all 433 
SARS-CoV-2 genomes. Two others, 1136R-E-Protein-gRNA1 and 1136S-N-Protein-gRNA1, 
matched 430 and 426 SARS-CoV-2 genomes, respectively. Of 3,164 non-SARS-CoV-2 viruses, 
the probes matched between 1 and 10 genomes, mostly from bat hosts (Summarized in Table S2). 
To identify a comprehensive set of possible targets that are specific to SARS-CoV-2 genomes, 
16,645 30 nt sequences that perfectly matched all 433 SARS-CoV-2 genomes were filtered to 
remove the ones that were also found in any of the 3,164 non-SARS-CoV-2 genomes to produce a 
set of 8,846 SARS-CoV-2-specific sequences (Table S4). To check for possible cross-reactivity 
with human transcripts, the probes were mapped to the human transcriptome (GRCh38, ENSEMBL 
release 99,  ftp://ftp.ensembl.org/pub/release-99/fasta/homo_sapiens/) comprising both coding and 
non-coding RNAs using bowtie 1.2.3 allowing up to two mismatches (-v 2). None of the 8,846 
sequences mapped to the human transcriptome to confirm their specificity to SARS-CoV-2. To 
visualize the distribution of the specific targets along the SARS-CoV-2 genome, probe density was 
calculated using a sliding window of 301 nt for each position of the reference SARS-CoV-2 genome 
NC_045512 (https://www.ncbi.nlm.nih.gov/nuccore/NC_045512) and plotted in R (Fig. S3). Viral 
genes that are affected by each probe were identified using the intersect function of bedtools (Table 
S3). 
 
RT-RPA amplification of viral genomic sequences 
Prior to all detection assays a pre-amplification step using RT-RPA was performed in order to 
amplify the SARS-CoV-2 target sequence. These protocols were initially developed and optimized 
on mock viral genome fragments and later validated against patient samples. To amplify the target 
sequences from the synthetic vRNA, we performed RT-RPA 38 (protocol summarized in Fig. S3).  
In short,  RT-RPA primers were designed to amplify 30 nt gRNA spacer regions flanked by 30 nt 
priming regions from the synthetic vRNA template while also incorporating a T7 promoter 
sequence into the 5’ end of the dsDNA gene fragment with +2 G’s thus increasing transcription 
efficiency (Fig. 1B) 90. RT-RPA was performed at 42℃ for 45 min by combining M-MuLV-RT 
(NEB #M0253L) with TwistAmp® Basic (TwistDx #TABAS03KIT). All RT-RPA primer 
sequences can be found in Table S1. 
 
Fluorescence-based detection of SARS-CoV-2 
For fluorescence-based detection, we developed a simple in vitro transcription-coupled cleavage 
assay with a fluorescence readout using 6-Carboxyfluorescein (6-FAM) as our fluorescent marker. 
To facilitate fluorescence detection, we developed a 6 nt poly-U probe conjugated to a 5’-6-FAM 
and a 3’-IABlkFQ (FRU, Table S5) and custom ordered from IDT. In total volumes of 15𝜇L, the 
following reaction mix was prepared; 5.62𝜇L water, 0.4𝜇L HEPES, pH 7.2 (1M), 0.18𝜇L MgCl2 
(1M), 3.2𝜇L rNTPs (25mM each), 2𝜇L CasRx (55.4 ng/𝜇L), 1𝜇L RNase inhibitor (40U/𝜇L), 0.6𝜇L 
T7 Polymerase (50U/𝜇L), 1 𝜇L gRNA (10 ng/𝜇L), and 1𝜇L FRU probe (2uM). This was followed 
by the addition of 5𝜇L (50% amplification vol) of the amplified target RNA from the RT-RPA pre-
amplification mix (described above) or no-template control, which initiates the reaction following 
incubation at 37℃ for 90 min. Experiments were immediately run on a LightCycler® 96 (Roche 
#05815916001) at 37℃ under 5 sec acquisition followed by 5 sec incubation for the first 15 min, 
followed by 5 sec acquisition and 55 sec incubation for up to 75 min. Fluorescence readouts were 
analyzed over-time by normalization to templateless controls at each respective time point or 
through background subtracted fluorescence by subtracting the initial fluorescence value from the 
final value. 
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Lateral Flow-based detection of SARS-CoV-2  
For lateral flow-based detection we modified the HybriDetect® system to detect the presence of 
SARS-CoV-2 sequences using SENSR 38. In brief, we designed a ssRNA probe composed of a 6 nt 
poly-U probe conjugated on opposite ends with a 5’-6-FAM and a 3’-biotin which was custom 
ordered from IDT (LFRU, Table S5). Following incubation of 5.22𝜇L water, 0.4𝜇L HEPES, pH 
7.2 (1M), 0.18𝜇L MgCl2 (1M), 2𝜇L CasRx (55.4ng/𝜇L), 1𝜇L gRNA (10 ng/𝜇L), 5𝜇L RT-RPA 
reaction mix, 1𝜇L T7 polymerase (50 U/mL), 3.2𝜇L rNTPs (25mM each), 1𝜇L LFRU probe (20 
uM), at 37℃ for 60 min. 80𝜇L of HybriDetect Assay buffer was added to each reaction and mixed 
thoroughly. Next, the lateral flow dipstick was placed into the reaction and allowed to flow upwards 
by capillary action for a maximum of 2 min. The presence or absence of upper or lower bands was 
analyzed to detect evidence of SARS-CoV-2 by collateral cleavage. The presence of a solitary upper 
band or both an upper and lower band indicates a positive result, a solitary lower band with a faint 
upper band was interpreted as a negative result. 
 
Patient samples ethics statement 
Human samples from patients were collected under University of California San Diego’s Human 
Research Protection Program protocol number 200470 for negatives (PI: Lauge Farnaes), and under 
a waiver of consent from clinical samples from San Diego County for positives (PI: Kristian 
Andersen), as part of the SEARCH Alliance activities. Samples were de-identified as required by 
these protocols prior to testing and analysis under University of California San Diego Biological 
Use Authorization protocols R1806 and 2401. 
 
RNA extraction and processing of patient samples 
Patient nasopharyngeal samples were collected and RNA was extracted using Omega Bio-Tek 
Mag-Bind Viral DNA/RNA 96 Kit (Omega Cat. No. M6246-03), following the manufacturer's 
protocol for KingFisher Flex platform.  
  
RT-qPCR validation of SARS-CoV-2 infection in patient samples 
Patient samples were determined to be SARS-CoV-2 positive or negative TaqPath™ COVID-19 
Combo Kit RT-qPCR assay as described in (https://www.fda.gov/media/136112/download), and 
reducing the RT-qPCR reaction volumes to 3µl and diluting the MS2 phage control to improve the 
limit of detection of the assay. The presence of SARS-CoV-2 viral RNA was analyzed using 
primers targeting the N, S, and Orf1ab genes with an MS2 control. All RT-qPCR assays were run 
using TaqPathTM 1-Step RT-qPCR Master Mix (ThermoFisher #A15299) and thermocycling 
conditions were run following the CDC recommended protocol 
(https://www.fda.gov/media/136112/download). Fluorescence data were acquired on a 
QuantStudio 5 qPCR machine (Applied Biosystems).   
 
SENSR detection of patient samples 
To detect the presence of SARS-CoV-2 in patient samples using SENSR, we tested this system 
against RT-qPCR validated samples. We obtained SARS-CoV-2 positive (N=21) and negative 
(N=21) samples and ran fluorescence analysis of these samples in triplicate. Samples were subject 
to preamplification using RT-RPA and incubated in an IVT-coupled cleavage reaction, as 
previously described. Data for analysis were acquired on LightCycler® 96 (Roche #05815916001) 
following the protocol previously described. We processed the data by generating background 
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subtracted fluorescence data for each replicate by subtracting the final (90 min) fluorescence value 
from the initial (0 min) fluorescence value. Noise was set as the average of the three no-template 
control (NTC) background subtracted values. S/N was then calculated by dividing the background 
subtracted value for each replicate by the noise. The S/N for each sample was then determined by 
taking the average of the three independent S/N ratios in the triplicates. Samples were determined 
to be positive if S/N > 2 and negative if S/N < 2.  Lateral flow analysis was run on samples that 
were determined as positives from the SENSR fluorescence analysis. The samples were assayed 
and analyzed following the previously described lateral flow methods and images were taken using 
a smartphone. Positives and negatives were determined in comparison to the NTC samples and 
using a positive control (synthetic template) as a standard.    
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Figure 1. Harnessing SENSR to detect evidence of SARS-CoV-2 viral transcripts. [A] 
Overview of assay workflow. Following extraction of viral RNA, the detection protocol requires 
three distinct steps, the last of which differs based on desired output detection method.  In the first 
reaction, specific target sequences within the viral RNA are reverse transcribed (RT) into cDNA 
and amplified by RPA at 42°C for 45m, while also adding T7 promoter sequences to the 5’ 
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terminus (T7, purple). In the next reaction, in vitro transcription occurs simultaneously with CasRx 
collateral cleavage activation (pink) by recognition and cleavage of the target RNA sequence 
(purple) through the sequence-specific targeting activity of the gRNA (emerald). Addition of a 
probe conjugated to fluorescein and a quencher can facilitate readout by fluorescence following 
probe cleavage (top right). Addition of a probe conjugated to fluorescein and biotin facilitates 
readout by lateral flow assay (bottom right). [B] Schematic of the SARS-CoV-2 genome, RPA reagents, 
gRNA target sites, and synthetic amplicon position. The E (envelope) and N (nucleocapsid) genes are 
enlarged to depict the design schematic in more detail (purple and blue respectively). The schematic depicts 
the relative position of the RT-RPA primers and gRNAs used in the amplification step. The gRNA target 
map outlines all six gRNAs tested through the course of this work, with their relative positions. The E-gene 
encompases 227 total nt while the N-gene encompases 1,260 nt, and gRNA lengths and positions are shown 
to scale.  Synthetic target amplicon denotes the length of the synthetic viral genome fragment used to test 
assay cleavage and its relative position within the gene coding sequence. [C] Preliminary characterization 
of CasRx fluorescence detection by N-targeting gRNAs (gRNA-Z, -AA, -AC) with the addition of 300 fM 
dsDNA template (N-gene template, 524bp) to an IVT-coupled cleavage reaction. Shown as Background 
Subtracted Units, A.U. over time (4 technical replicates each, Mean and SEM). gRNA-Z was selected for 
further downstream analysis. [D] Preliminary characterization of CasRx fluorescence detection by E-
targeting gRNAs (gRNA-R, -T, -V) with the addition of 300 fM dsDNA template (E-gene template, 253 
bp) to an IVT-coupled cleavage reaction. Plotted as Background Subtracted Units, A.U. over time (4 
technical replicates each, Mean and SEM). gRNA-T was selected for further downstream analysis. [E] The 
in vitro cleavage properties of the E-targeting gRNA-T. In Lane 1 the absence of gRNA-T results in no 
cleavage of the E-gene fragment (228 nt). In Lane 2 the addition of gRNA-T results in cleavage of the E-
gene template resulting in loss of the distinct 228 nt band and appearance of lower molecular weight 
cleavage species. In Lane 3, the off-target N-gene template (500 nt) remains uncleaved in the presence of 
CasRx and the E-targeting gRNA-T. In Lane 4, the absence of CasRx results in no cleavage of either E or 
N-gene templates. In Lane 5, the on-target cleavage of the E-gene template results in additional collateral 
cleavage of the N-gene template, resulting in the loss of both bands from the gel and the accumulation of 
lower molecular weight cleavage products. [F] The in vitro cleavage properties of the N-targeting gRNA-
Z. In Lane 1, the absence of gRNA-Z results in no cleavage of the N-gene fragment (500 nt). In Lane 2, the 
addition of gRNA-Z results in cleavage of the N-gene template resulting in loss of the distinct 500 nt band 
and appearance of lower molecular weight cleavage species. In Lane 3, the off-target E-gene template (228 
nt) remains uncleaved in the presence of CasRx and the N-targeting gRNA-Z. In Lane 4, the absence of 
CasRx results in no cleavage of either E or N-gene templates. In Lane 5, on-target cleavage of the N-gene 
template results in additional collateral cleavage of the E-gene template, resulting in the loss of both bands 
from the gel and the accumulation of lower molecular weight cleavage products. 
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Figure 2. SARS-CoV-2 detection by SENSR via Fluorescence and Lateral Flow assay.  [A] Cleavage 
properties of E-targeting gRNA-T in fluorescence context. Fluorescence detection of E-gene in an IVT-
coupled coupled context. gRNA-T incubated in three different contexts: with E-gene template, with N-gene 
template, or with both E- and N-gene template. Accumulation of fluorescence occurs when gRNA-T is 
incubated with the E-gene target template leading to cleavage of the ssRNA probe. Collateral cleavage is 
not observed when gRNA-T is incubated with the non-target N-gene template.  [B] Cleavage properties of 
N-targeting gRNA-Z in fluorescence context. Fluorescence detection of N-gene in an IVT-coupled coupled 
context. gRNA-Z incubated in three different contexts: with N-gene template, with E-gene template, or 
with both N- and E-gene template. Accumulation of fluorescence occurs when gRNA-Z is incubated with 
the N-gene target template leading to cleavage of the ssRNA probe. Collateral cleavage is not observed 
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when gRNA-Z is incubated with the non-target E-gene template. [C] CasRx nucleic acid limit of detection 
(LOD) for gRNA-Z detection via fluorescence following cleavage of N-gene target. Total copy number of 
10000, 1000, 100, 10, or 0 of viral RNA template input into initial RT-RPA reaction, followed by CasRx 
detection by fluorescence. Performing a one-way ANOVA followed by a Dunnett’s test call copy numbers 
to the NTC significance was found for 10000, 1000, and 100 copies (p<0.0001) and no significance was 
found for 10 copies (p=0.9999). Results shown as background-subtracted fluorescence (A.U.) following 90 
minute fluorescent readout (4 technical replicates each, Mean and SD). [D] CasRx nucleic acid LOD for 
gRNA-T detection via fluorescence following cleavage of E-gene target. Total copy number of 10000, 
1000, 100, 10, or 0 of viral RNA template input into initial RT-RPA reaction, followed by CasRx detection 
by fluorescence. Performing a one-way ANOVA followed by a Dunnett’s test call copy numbers to the 
NTC significance was found for 10000, 1000, and 100 copies (p<0.0001) and no significance was found 
for 10 copies (p>0.9999). Results shown as background-subtracted fluorescence (A.U.) following 90 
minute fluorescent readout (4 technical replicates each, Mean and SD). [E] LOD of the gRNA-Z recognition 
of N-gene target by lateral flow assay. CasRx detection reaction incubated for 1h prior to lateral flow assay. 
[F] LOD of the gRNA-T recognition of E-gene target by lateral flow assay. CasRx detection reaction 
incubated for 1h prior to lateral flow assay.  
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Figure 3. SENSR detection of positive SARS-CoV-2 validated patient samples.  [A] SENSR 
fluorescence analysis of RT-qPCR validated patient samples using gRNA-Z for detection. Samples 1-21 
are patient samples positive for SARS-CoV-2 listed in order of ascending RT-qPCR Ct values for the N-
gene where low Ct value is equal to a high viral load. The black and gray rings represent the Ct values for 
N, S, and Orf1ab genes, where black represents the N-gene Ct values and gray represents the S and Orf1ab 
Ct values. Samples N1-N5 are the five samples negative for SARS-CoV-2 with the highest recorded signal-
to-noise ratios (S/N) of all negative samples analyzed with the highest S/N = 1.8. The dashed line represents 
the S/N = 2 threshold used to determine a positive detection of SARS-CoV-2. The asterisks indicate a 
positive detection of SARS-CoV-2 in the patient sample. [B] Summary of fluorescence detection results 
for the RT-qPCR validated positive and negative patient samples. [C] Lateral flow based detection of the 
12 samples from [A] that resulted in a positive detection of SARS-CoV-2 (S/N > 2). The top band represents 
the test band and the bottom the control band. An increase in saturation of the top band indicates a positive 
detection of SARS-CoV-2 in the sample. A positive result was also determined by comparing to the NTC, 
which served as a baseline for a negative result. 
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SUPPLEMENTARY FIGURES 
 
 
Supplementary Figure 1.  Summary of current CRISPR-based anti-Covid technologies organized by 
Cas enzyme used and by role as diagnostic or detection tool, or as a putative prophylactic.  Those 
technologies shown in black font have been demonstrated to have explicit activity against SARS-CoV-2, 
while those technologies shown in grey font have been publicly discussed or proposed to be technological 
candidates for SARS-CoV-2 detection or prophylaxis, however have not yet been fully 
demonstrated/optimized for said purpose as of the publication of this manuscript.  Some technologies have 
not yet been given a formal name by their authors, and are therefore denoted as ‘unnamed’ followed by the 
acronym for the primary institutional affiliation behind the work. To better identify and distinguish these 
technologies, the DOI has been provided. [Diagnostics/detection systems/Mass testing]  For all 
technologies viral RNA is extracted, reverse transcribed into cDNA, followed by template amplification by 
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either PCR, RPA or LAMP, then input into subsequent reactions with the exception of CRISPR-Chip which 
does not require an amplification step. Cas12-based enzymes, as well as many other Cas proteins (including 
Cas9) recognize DNA species, while Cas13-based enzymes recognize ssRNA, and all can be used to detect 
evidence of specific sequences by fluorescence or lateral flow. The detection method for each technology 
is noted with the presence of an icon adjacent. The majority of the technologies summarized here use 
fluorescence or lateral flow or both. The lime glow icon indicates readout by fluorescence, while the grey 
bar indicates read-out by lateral flow. Some of the other technologies can be read out by different detection 
methods. Notably because FELUDA relies on direct sequence cleavage, and not the collateral cleavage 
property shared amongst the Cas12- and Cas13-based technologies, it can also be analyzed by gel 
electrophoresis as evidence of distinct band cleavage (aqua gel icon). Also, CRISPR-Chip has been 
discussed as a SARS-CoV-2 mass detection candidate, though these findings have not yet been made 
publicly available. Read-out by this technology is achieved via a graphene-based transistor (icon is red, 
grey with graphene structure adjacent). Other different technologies include CREST, which achieves 
detection via fluorescence using a distinctly do-it-yourself (DIY) BioHacking approach, by utilizing 
equipment easily procured and operated by novice scientists, as well as CARMEN-Cas13 which detects 
evidence of SARS-CoV-2 sequences by microarray. The technology outlined here is an addition to current 
SHERLOCK detection utilizing Cas13d (CasRx). The technical details of most technologies is summarized 
in Table S1. 
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Supplementary Figure 2. CasRx protein purification workflow and quality control. [A] CasRx protein 
was produced and purified essentially as described in (Konermann et al. 2018). A CasRx protein-expression 
plasmid was generated with CasRx (pink) downstream of a Maltose-binding protein (MBP, purple) domain 
with an N-terminal 6xHis tag (blue),  connected by a TEV protease cleavage sequence (green). Origin of 
replication and KanR cassette shown in navy. Transformation of the plasmid into Rosetta2TM (DE3) 
Competent E. coli was followed by large scale culture growth. Cell lysate supernatant containing 6xHis-
MBP-CasRx soluble hybrid protein was run on a Ni-NTA column for purification by affinity 
chromatography. CasRx protein was then released from the 6xHis-MBP moiety by TEV protease cleavage 
during O/N dialysis, and was further purified by cation exchange and size exclusion using Fast Protein 
Liquid Chromatography (FPLC). [B] The cation exchange elution profile of CasRx with the concentration 
of NaCl (mM) shown in blue. Peak containing CasRx recombinant protein (boxed in gold) elutes at ~700 
mM NaCl. [C] The SEC elution profile of CasRx recombinant protein following Size Exclusion 
Chromatography (SEC) (blue). Peak containing CasRx recombinant protein highlighted boxed in gold.  [D] 
A 10% SDS-PAGE  gel showing protein species present at different stages of the purification protocol. 
Lane 1 is SeeBlue™ Plus2 Pre-stained Protein Standard with the predicted final CasRx protein size marked 
at right in pink at approximately 112 kDa. Lane 2 is a resuspended cell pellet. Lane 3 is cell lysate 
supernatant. Lane 4 is cell lysate pellet. Lane 5 is Ni-NTA flow through. Lane 6 is Ni-NTA Elution. Lane 
7 is the sample post O/N Dialysis. Lane 8 is the sample after IEC, and Lane 9 is the concentrated Final 
Sample post-SEC. 
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Supplementary Figure 3.  Molecular scale overview of CasRx detection protocol workflow. Bracketed 
into the two base component reactions, RT-RPA or IVT + cleavage.  [Panel 1A] Viral ssRNA is extracted 
and reverse transcribed into cDNA. A fragment of the viral E-gene ssRNA (navy), with the final CasRx 
target site highlighted (mint). Reverse transcriptase (raspberry) actively reverse transcribes the viral 
template into cDNA. [Panel 2A] In the simultaneous RPA reaction, recombinase (brown) binds to the 
primer (red and orange) with D-loops formed at binding sites.  [2B] Recombinase helps anneal the primer 
to the target site, and single strand binding protein (SSB, teal) begins annealing to ssDNA to stabilize the 
strand and reaction. [Panel 3A] Strand-displacing DNA polymerase (grey) amplifies the target DNA, with 
continued binding of SSB to ssDNA for stabilization. [Panel 4A] DNA amplicon extension is completed, 
[4B] while polymerase simultaneously dislodges SSB, and [4C] the T7 promoter region (orange) is added 
to the amplicon via primer extension. [Panel 5] The final product of the RT-RPA reaction is a small 
amplified fragment of target DNA encompassing the CasRx target site, with a T7 promoter added for 
subsequent IVT. [Panel 6A] T7 RNA polymerase-based in vitro transcription (blue) occurs, initiated from 
the T7 promoter (orange) in order to generate ssRNA (magenta) required as the activation substrate of 
CasRx. [6B] Elongation of the ssRNA template takes place. [Panel 7] CasRx detection of on-target 
sequence, activation of collateral cleavage activity, and detection. [7A] The CasRx/gRNA complex (pink 
and green) recognize, [7B] bind to, and cleave (red scissors) the ssRNA viral target template (magenta). 
[7C] This action activates the collateral cleavage property of CasRx (gold, black scissors). [7D] Following 
activation, collateral cleavage of an included small ssRNA probe can be analyzed via [7E] fluorescence or 
lateral flow assay.  
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Supplementary Figure 4. Depiction of unique gRNA target sequences across SAR-
CoV-2 genome. Spread of unique and specific 30 nt putative gRNA target sequences 
(Table S3-S5) displayed across the SARS-CoV-2 genome, smoothened over a 301 nt 
window. Higher specificity score indicates higher density of unique and conserved targets.  
Representative genome map shown at bottom with ORFs and genes annotated.  E-gene 
ORF highlighted in orange with beige vertical bar highlighting the zero specificity score 
of the gene. 
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Supplementary Figure 5. Preliminary in vitro cleavage assays for guides tested throughout this work. 
[A] Summary map of gRNA target location within the SARS-CoV-2 genome. gRNA-R, -T, -V target the 
Envelope (E) gene, and gRNA-Z, -AA, -AC target the Nucleocapsid (N) gene. [B] In vitro on-target 
cleavage assays for the six guides developed in the first cohort (R, T, V). Equimolar amounts of N and E 
synthetic RNA fragments (500 nt and 228 nt respectively) were incubated at room temperature (RT) in the 
presence or absence of their on-target gRNA, named above. The on-target gene is denoted with (E) or (N) 
for each gRNA, and is shown mapped in [A]. The presence of the gRNA initiates cleavage of both the on-
target template in addition to collateral cleavage of the off-target template. [C] On-target in vitro cleavage 
assays for the conserved and specific N-targeting gRNA-Z, -AA, -AC. In each reaction the 500 nt N-gene 
synthetic RNA fragment is provided, and the presence or absence of CasRx initiates on-target cleavage of 
the template into smaller fragments.  
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Supplementary Figure 6. Optimizing SENSR Fluorescence detection assay. [A] Determining optimal 
sequence for collateral cleavage probe. Collateral cleavage of Poly-A probe is tested in the first group, Poly-
U is tested in the second, and RNase Alert in the third group. Within each group, gRNA-T and gRNA-Z 
are incubated in  a reaction saturated with 10,000 (10k) target copies, or 0 (Neg Ctrl) as a negative control. 
Performing a two-tailed t-test of unequal variance comparing each 10k group to the respective Neg Ctrl 
groups a significant increase in fluorescence was only found for the Poly-U probe 10k groups (gRNA-T 
10k: p<0.0001, gRNA-Z 10k: p<0.0001). No significant increase in fluorescence was observed for the 10k 
Poly-A or 10k RNase Alert groups compared to the respective Neg Ctrl groups for gRNA-T (Poly-A: 
p=0.5953, RNase Alert: p=0.4294) or gRNA-Z (Poly-A: p=0.7935, RNase Alert: p=0.1510). Performing a 
one-way ANOVA followed by a Dunnett’s test comparing the 10k groups of the Poly-A and RNase Alert 
groups to the 10k Poly-U groups a significant difference was found for both gRNA-T (Poly-A: p<0.0001, 
RNase Alert: p<0.0001) and gRNA-Z (Poly-A: p<0.0001, RNase Alert: p<0.0001). Bars indicate mean ± 
SD of background subtracted fluorescence from three technical replicates. [B] Determining the optimal 
input volume of RT-RPA sample into SENSR reaction. In all cases the trial sample is equivalent to 100 
copies/𝜇L (blue), the positive control is established with 10,000/𝜇L (dark grey), and the negative control is 
no-template control (pale grey).  In the left most grouping the RT-RPA template sample input into the 
SENSR reaction comprises 10% of the preamplification reaction, in the middle grouping it composes 20% 
of the preamplification reaction, and in the final grouping it comprises 50% of the preamplification reaction. 
Performing a one-way ANOVA followed by a Dunnett’s test within each % input group significance was 
only found for both the sample (p<0.0001) and positive control (p<0.0001) in the 50% group (10%: Sample 
- p= 0.8925, Pos Ctrl - p<0.0001; 20%: Sample - p=0.8160, Pos Ctrl - p<0.0001). Performing a second one-
way ANOVA followed by a Dunnett’s test comparing the 50% sample group to the 10% and 20% sample 
groups, a significant increase in fluorescence was observed (10%: p<0.0001, 20%: p<0.0001). Bars indicate 
mean ± SD of background subtracted fluorescence from three technical replicates.  
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Supplementary Figure 7. Assessment of gRNA specificity within the SENSR system. Schematic 
representation of gRNA mismatches for the four most closely related sequences (off-targets, OT1-OT4) 
identified via BLAST for [A] gRNA-T and [B] gRNA-Z. [C] gRNA-T demonstrated no off-target activity 
on the 4 closely related sequences.  Bars indicate mean ± SD of background subtracted fluorescence from 
three technical replicates. Performing a one-way ANOVA followed by a Dunnett’s test comparing to the 
NTC fluorescence signal was found to be significant for the E-gene compared (p<0.0001), however no 
significant fluorescence signal increase was found for the four off-targets (OT1: p=0.9998, OT2: p=0.5242, 
OT3: p=0.6633, OT4: p=0.8475). Performing a one-way ANOVA followed by a Dunnett’s test comparing 
to the E-gene positive control significant fluorescence signal increase was found when targeting the E-gene 
compared to the four off-targets (OT1, OT2, OT3, OT4: p<0.0001).  [D] Collateral cleavage was observed 
for two of the closely related off-targets for gRNA-Z .  Bars indicate mean ± SD of background subtracted 
fluorescence from three technical replicates. Performing a one-way ANOVA followed by a Dunnett’s test 
comparing to the NTC fluorescence signal increase was found to be significant for the N-gene positive 
control, OT1, and OT2 (N, OT1, OT2: p<0.0001), however no significant fluorescence signal increase was 
found for OT3 and OT4 (OT3: p=0.8877, OT4: p>0.9999). Performing a one-way ANOVA followed by a 
Dunnett’s test comparing to the N-gene positive control, significant fluorescence signal increase was found 
to when targeting the N-gene compared to OT3 and OT4 (OT3, OT4: p<0.0001), but no significant 
difference was found targeting the N-gene compared to OT1 and OT2 (OT1: p=0.0786, OT2: p=0.0833). 
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Supplementary Figure 8. In addition to RNA-based templates (top row), SENSR technology could also 
be used for DNA-based templates, including, but not limited to, bacterial samples (shown) as well as DNA 
viruses such as herpes (shown, bottom, navy).  DNA-based sample templates can be input directly into the 
RPA amplification reaction, negating the need for a simultaneous reverse transcription (RT) reaction as is 
required for RNA-based templates. Like SENSR on RNA-based templates, the reaction occurs in two steps. 
The first amplification step, RT-RPA or RPA, is followed by the SENSR reaction which is identical 
regardless of initial input molecular species. This reaction is composed of simultaneous in vitro 
transcription (IVT) as well as CasRx cleavage and activation of collateral cleavage activity. The assay can 
be read out by fluorescence or lateral flow in the same fashion regardless of DNA or RNA sample input. 
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--------------------------------------SUPPLEMENTARY TABLES-------------------------------------- 
 
 
Supplementary Tables  
 
Table S1. Summary Table of current, and possible future, CRISPR-based anti-Covid technologies.  
 
Table S2. Analysis identifying putative 30nt gRNA target sites conserved across, and specific to the SARS-
CoV-2 genome. 
 
Table S3. Predicted unique and conserved 30nt CasRx gRNA target sequences to SARS-CoV-2. 
 
Table S4. Analysis of Inter-SARS-CoV-2 Conservation (433 genomes) and Pan-coronavirus Specificity 
(3164 genomes)  on the three E-targeting gRNAs (R,T,V). 
 
Table S5. List and sequences of reagents generated and used throughout this work. Primers for cloning, 
gRNA prep, and RT-RPA, as well as gRNA sequences, viral gene templates, plasmid sequences and probes.   
 
Table S6. Top four naturally-occurring off-target sequences for gRNA T and gRNA Z. 
 
Table S7. Data from RT-qPCR and SENSR fluorescence analysis of patient samples for detection of SARS-
CoV-2. 
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